The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Level 5 - mechanism / opinion, no new human data
Clinical practice guideline and expert consensus without new primary data
PubMed 24918167 · doi:10.1038/clpt.2014.125
What was done
The Clinical Pharmacogenetics Implementation Consortium (CPIC) reviewed published literature regarding the SLCO1B1 rs4149056T>C polymorphism and simvastatin-induced muscle toxicity to provide updated genotype-based therapeutic recommendations.
What was found
The abstract reports no numerical data or effect sizes. It states qualitatively that the rs4149056T>C variant increases systemic exposure to simvastatin and increases the risk of muscle toxicity.
Why it matters
It provides structured clinical recommendations to help prescribers adjust simvastatin therapy according to patient genotype to prevent adverse drug events.
Limits
The abstract lacks details on the literature search methodology, study inclusion criteria, sample sizes, and quantitative risk estimates.
Cited by
- supports Genetic testing can identify individual susceptibility to statin-induced myopathy and muscle damage.